吉西他滨与白蛋白结合型紫杉醇联合阿法替尼治疗转移性胰腺癌——一项1b期临床试验结果
这项1b期试验在初治转移性胰腺导管腺癌患者中,将吉西他滨/白蛋白结合型紫杉醇与口服阿法替尼联合,采用3+3设计确定最大耐受剂量。12例入组、11例可分析,剂量水平0未出现剂量限制性毒性,剂量水平+1有2例出现剂量限制性毒性,最终确定最大耐受剂量为吉西他滨/白蛋白结合型紫杉醇1000 mg/m²/125 mg/m²联合阿法替尼30 mg。
要点
- 最大耐受剂量为吉西他滨/白蛋白结合型紫杉醇1000 mg/m²/125 mg/m²联合阿法替尼30 mg。
- 7例(63.6%)发生至少1次治疗中出现严重不良事件,4例(36.4%)发生与研究药物相关的3-5级严重不良事件。
- 可分析人群中客观缓解率36.4%,中位无进展生存期3.5个月,9例可评估患者中位总生存期7.5个月。
核心结论
- 本1b期试验确定吉西他滨/白蛋白结合型紫杉醇(1000 mg/m²/125 mg/m²)联合阿法替尼(30 mg)的最大耐受剂量;在11例患者队列中,该联合方案显示可接受的安全性。
研究设计与样本
- 1b期临床试验,采用3+3设计确定最大耐受剂量;入组≥18岁、组织学证实转移性胰腺导管腺癌、ECOG 0/1、未经治疗的患者。
- 治疗从剂量水平0开始:静脉吉西他滨/白蛋白结合型紫杉醇1000 mg/m²/125 mg/m²(28天周期第1、8、15天)联合口服阿法替尼30 mg每日;剂量水平+1将阿法替尼增至40 mg。
- 共12例入组,11例接受治疗并纳入安全性和全分析集;主要终点为最大耐受剂量,次要终点包括安全性参数,探索性终点评估疗效。
主要发现
- 剂量水平0的前3例患者未出现剂量限制性毒性;剂量水平+1有2例出现剂量限制性毒性。
- 随后在剂量水平0继续入组3例,其中1例出现剂量限制性毒性(皮疹≥CTCAE 3级)。
- 7例(63.6%)发生至少1次治疗中出现严重不良事件,4例(36.4%)发生与研究药物相关的3-5级治疗中出现严重不良事件。
- 全分析集客观缓解率36.4%,中位无进展生存期3.5个月,9例可评估患者中位总生存期7.5个月。
关键数值与推荐
- 最大耐受剂量:吉西他滨/白蛋白结合型紫杉醇1000 mg/m²/125 mg/m²联合阿法替尼30 mg。
- 剂量水平0:前3例无剂量限制性毒性;剂量水平+1:2例出现剂量限制性毒性。
- 全分析集:客观缓解率36.4%,中位无进展生存期3.5个月,9例可评估患者中位总生存期7.5个月。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The combination of gemcitabine/nab-paclitaxel is an established standard treatment in the first-line treatment of metastatic ductal adenocarcinoma of the pancreas (mPDAC). Afatinib, an oral second-generation pan ErbB family tyrosine kinase inhibitor, has shown promising pre-clinical signs in the treatment of pancreatic cancer. The aim of this phase 1b trial was to determine the maximum tolerated dose (MTD) of afatinib in combination with gemcitabine/nab-paclitaxel in patients with mPDAC. METHODS: Treatment naïve patients (≥18 years) with histologically proven mPDAC and good performance status (ECOG 0/1) were enrolled to receive gemcitabine/nab-paclitaxel in combination with afatinib. Treatment was continued until disease progression, or unacceptable toxicity. The primary endpoint MTD was determined using a 3 + 3 design. Treatment started at dose level 0 with intravenous gemcitabine/nab-paclitaxel 1000 mg/m2 / 125 mg/m2 (day 1, 8, 15 of a 28-day cycle) + oral afatinib 30 mg daily. At dose level + 1 afatinib was increased to 40 mg. Secondary endpoints included safety parameters and exploratory endpoints evaluated treatment efficacy. RESULTS: Twelve patients were included in this trial, and 11 patients were treated and analysed in the safety and full analysis set (FAS). At dose level 0 the first three patients did not experience a dose-limiting toxicity (DLT). At dose leve (DL) + 1 two patients experienced a DLT. Accordingly, enrolment continued at DL 0 with three more patients, of which one experienced DLT (skin rash ≥ CTCAE grade 3). Seven patients (63.6%) experienced at least one treatment-emergent serious adverse event (TESAE), with four patients (36.4%) experiencing TESAEs grade 3-5 related to the study medication. In the FAS, the objective response rate (ORR) was 36.4%, median progression-free survival (PFS) was 3.5 months and median overall survival in nine evaluable patients was 7.5 months. CONCLUSIONS: In this phase 1b clinical trial, the MTD of gemcitabine/nab-paclitaxel (1000 mg/m2 / 125 mg/m2) and afatinib (30 mg) was established. In a cohort of 11 patients, the combination showed an acceptable safety profile.
引用
- Zhang D, Benedikt Westphalen C, Quante M, et al. Gemcitabine and nab-paclitaxel combined with afatinib in metastatic pancreatic cancer - Results of a phase 1b clinical trial. Eur J Cancer. 2024. PMID: 38401449. doi:10.1016/j.ejca.2024.113926
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。